Alternative whooping cough vaccines: A minireview
MetadataShow full item record
This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/ Please refer to the licence to obtain terms for any further reuse or distribution of this work.
Bordetella pertussis, the aetiological agent of an acute upper respiratory tract disease of humans, “whooping cough”, can infect all age groups with adolescents and adults acting as major source of transmission of this pathogen to infants. This transmission is promoted by the fact that adolescents and adults do not exhibit the characteristic cough, the infection being either asymptomatic or manifested as a mild but persistent upper respiratory tract infection. It is established now that both antibodies and cell-mediated immune [CMI] responses are crucial for protection against whooping cough, the former being important in the early phase of the disease, with the latter being important forlong-term protection. The protection offered by vaccination with the currently-marketed acellular pertussis vaccines is predominantly due to antibodies against vaccine antigens associated with a Th2-polarised immune response and has been found to be relatively short-term protection. There is an urgent need to develop alternative vaccines capable of inducing both protective antibody and CMI responses particularly given the resurgence of this vaccinepreventable disease in infants and children worldwide. While current strategies are aimed at the development of recombinant vaccines using an adjuvant that may stimulate both arms of the immune response, no discovery of a cost-effective and non-toxic adjuvant to improve protection against pertussis has been reported thus far. This reviewdetails the oral presentation on alternative whooping cough vaccines and their future potential delivered at the 2nd World Conference on Vaccines and Vaccination organised by the OMICS Publishing Group.
Showing items related by title, author, creator and subject.
Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performanceDorji; Mooi, F.; Yantorno, O.; Deora, R.; Graham, Ross; Mukkur, Trilochan (2018)© 2017, Springer-Verlag GmbH Germany. Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis ...
Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidateCornford-Nairn, R.; Daggard, G.; Mukkur, Trilochan (2012)We describe the construction and immunobiological properties of a novel whooping cough vaccine candidate, in which the aroQ gene, encoding 3-dehydroquinase, wasdeleted by insertional inactivation using the kanamycin ...
Immunogenicity and protective potential of Bordetella pertussis biofilm and its associated antigens in a murine modelDorji, Dorji; Graham, Ross; Singh, Abhishek; Ramsay, Joshua; Price, Patricia; Lee, Silvia (2019)© 2019 Elsevier Inc. The resurgence of whooping cough reflects novel genetic variants of Bordetella pertussis and inadequate protection conferred by current acellular vaccines (aP). Biofilm is a source of novel vaccine ...